Hong Kong Exchanges and Clearing Limited and The Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(A joint stock limited company established in the People's Republic of China)
(Stock Code: 8197)
The board of directors the ("Board") of Northeast Tiger Pharmaceutical Co., Ltd.* (the "Company") is pleased to announce that all the resolutions proposed at the extraordinary general meeting (the "EGM") held on 10 January 2016, as set out in the circular of the Company dated 21 December 2015 (the "Circular"), were duly passed by the shareholders by way of poll.
Reference is made to the Circular. Capitalised terms used herein have the same meanings as defined in the Circular unless the context requires otherwise.
The EGM was held at No.3, No.2 Road, Jilin HiTech Development Zone, Jilin City, Jilin Province, the PRC on 10 January 2016 at 9:00 a.m., poll voting was taken for voting on the proposed resolutions. The Board is pleased to announce that the poll results in respect of the resolutions proposed at the EGM were as follows:
Ordinary Resolutions | For No. of votes (%) | Against No. of votes (%) | Total number of votes cast | |
1. | To consider and approve the appointment of Mr. Wang Shaoyan as an executive director of the Company and authorise the board of directors of the Company to fix his remuneration and finalise the terms of the service | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Ordinary Resolutions | For No. of votes (%) | Against No. of votes (%) | Total number of votes cast | |
2. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Ms. Cui Bingyan as an executive director o f t h e Company and authorise the board of directors of the Company to fix his | ||||
remuneration and finalise the terms of the service | ||||
3. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Mr. Guo Aiqun as a nonexecutive director of the Company and authorise the board of directors of the Company to fix his | ||||
remuneration and finalise the terms of the service | ||||
4. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Mr. Zhang Jinlong as a nonexecutive director of the Company and authorise the board of directors of the Company to fix his | ||||
remuneration and finalise the terms of the service | ||||
5. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Mr. Chen Youfang as an independent non executive director of the Company and authorise the board of directors of the Company to fix | ||||
his remuneration and finalise the terms of the | ||||
6. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Ms. Yang Lixue as a supervisor of the Company and authorise the board of directors of the Company to fix her remuneration and | ||||
finalise the terms of the service contract | ||||
7. | To consider and approve the appointment of | 531,289,600 (100%) | 0 (0%) | 531,289,600 |
Ms. Lin Xiarong as a supervisor of the Company and authorise the board of directors of the Company to fix her remuneration and | ||||
finalise the terms of the service contract | ||||
Special Resolutions | ||||
1. | To consider and approve the proposed | 531,289,600 | 0 | 531,289,600 |
amendment to the term of office of Ms. Hui | ||||
Lai Yam as an independent non executive | ||||
director of the Company for a period of three | (100%) | (0%) | ||
years commencing from the date of the | ||||
Extraordinary General Meeting | ||||
2. | To consider and approve the proposed | 531,289,600 | 0 | 531,289,600 |
amendments to the Articles of Association of | (100%) | (0%) | ||
As more than half and twothirds of the votes were casted in favour of the ordinary and special resolutions, respectively, all resolutions were duly passed.
As at the date of the EGM, the total number of issued shares of the Company was 746,654,240 comprising 539,654,240 domestic shares and 207,000,000 H shares listed on the Stock Exchange, representing the total number of shares entitling the holders to attend and vote for or against the resolutions at the EGM. There was no restriction imposed on Shareholders to cast votes on any of the aforesaid resolutions passed at the EGM.
SCOPE OF WORK OF PANCHINA (H.K.) CPA LIMITED
The poll results were subject to scrutiny by PanChina (H.K.) CPA Limited, whose work was limited to certain procedures requested by the Company to agree the poll results summary prepared by the Company to poll forms collected and provided by the Company to PanChina (H.K.) CPA Limited. The work performed by PanChina (H.K.) CPA Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants nor did it include provision of any assurance or advice on matters of legal interpretation or entitlement to vote.
By Order of the Board Wang Shaoyan
Chairman
Jilin, PRC
10 January 2016
As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo, the Company's nonexecutive directors are Guo Aiqun and Zhang Jinlong and the Company's independent nonexecutive directors are Chen Youfang, Zhao Zhen Xing and Hui Lai Yam.
This announcement, for which the directors of Northeast Tiger Pharmaceutical Co., Ltd.* collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Northeast Tiger Pharmaceutical Co., Ltd.* The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading.
This announcement will remain on the "Latest Company Announcements" page of the
GEM website at http://www.hkgem.com for at least 7 days from the day of its posting and on the website of the Company at http://www.northeasttiger.com.
* for identification purposes only
Northeast Tiger Pharmaceutical Co. Ltd. issued this content on 2016-01-10 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-10 12:27:04 UTC
Original Document: http://www.northeasttiger.com/leichinews/Upload/20161102012444.pdf
